Feasibility of remote interviews in assessing disease severity in patients with major depressive disorder: A pilot study

被引:1
作者
Sumiyoshi, Tomiki [1 ,8 ]
Morio, Yasunori [1 ]
Kawashima, Takahiro [1 ]
Tachimori, Hisateru [1 ]
Hongo, Seiji [2 ]
Kishimoto, Taishiro [3 ,4 ]
Watanabe, Koichiro [5 ]
Otsubo, Tempei [6 ]
Oi, Hideki [1 ]
Nakagome, Kazuyuki [1 ]
Ishigooka, Jun [7 ]
机构
[1] Natl Ctr Neurol & Psychiat, Tokyo, Japan
[2] Ichigaya Himor Clin, Tokyo, Japan
[3] Keio Univ, Hills Joint Res Lab Future Prevent Med & Wellness, Sch Med, Tokyo, Japan
[4] Donald & Barbara Zucker Sch Med Hofstra Northwell, Psychiat Dept, Hempstead, NY USA
[5] Kyorin Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan
[6] Tokyo Womens Med Univ, Dept Psychosomat & Psychiat Med, Adachi Med Ctr, Tokyo, Japan
[7] Ishigooka Hosp, Chiba, Japan
[8] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Dept Prevent Intervent Psychiat Disorders, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878551, Japan
关键词
major depressive disorder; mobile applications; pilot project; psychiatric status rating scale; psychological interviews; RELIABILITY; QUALITY; TRIALS;
D O I
10.1002/npr2.12411
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
AimInterview quality is an important factor in the success of clinical trials for major depressive disorder (MDD). There is a substantial need to establish a reliable, remote clinical assessment interview system that can replace traditional in-person interviews.MethodsWe conducted a multicenter, randomized, unblinded, prospective, cross-sectional study to assess the reliability of remote interviews in patients with MDD (UMIN000041839). Eligible patients with MDD underwent remote and in-person sessions of the Montgomery-angstrom sberg Depression Rating Scale (MADRS) assessment performed by different raters within 28 days of providing consent. Patients were randomized to a group first assessed using in-person interviews and secondarily using remote interviews (in-person-first group) or a group first assessed by remote interviews and secondarily using in-person interviews (remote-first group). Nineteen trained people (15 clinical psychologists, 3 nurses, and 1 clinical laboratory technologist) performed interviews.ResultsOf 59 patients (in-person-first group, n = 32; remote-first group, n = 27) who completed both remote and in-person interviews, 51% (n = 30) were women; the mean age was 41.6 years (range, 21-64 years). There was a strong association between remote and in-person MADRS scores (r = 0.891, kappa = 0.901). An overall intraclass correlation coefficient (ICC) of 0.886 (95% confidence interval, 0.877-0.952) indicated good consistency between MADRS scores in remote and in-person interviews. The ICC decreased as the severity of depression increased.ConclusionOur results suggest remote interviews are a feasible alternative option to in-person interviews in assessing symptom severity in MDD patients and could promote clinical trials in Japan. In a multicenter, randomized study of 59 Japanese patients with major depressive disorder, we found that remote interviews are a feasible alternative option to in-person interviews in assessing symptom severity by the Montgomery-angstrom sberg Depression Rating Scale.image
引用
收藏
页码:149 / 157
页数:9
相关论文
共 50 条
  • [21] Increased spinal pain sensitization in major depressive disorder: A pilot study
    Tikasz, Andras
    Tourjman, Valerie
    Chalaye, Philippe
    Marchand, Serge
    Potvin, Stephane
    PSYCHIATRY RESEARCH, 2016, 246 : 756 - 761
  • [22] Potential Major Depressive Disorder Biomarkers in Pediatric Population - a Pilot Study
    Krivosova, Michaela
    Grendar, Marian
    Hrtanek, Igor
    Ondrejka, Igor
    Tonhajzerova, Ingrid
    Sekaninova, Nikola
    Bona Olexova, Lucia
    Mokra, Daniela
    Mokry, Juraj
    PHYSIOLOGICAL RESEARCH, 2020, 69 : S523 - S532
  • [23] A Pilot Study on the Decoding of Dynamic Emotional Expressions in Major Depressive Disorder
    Esposito, Anna
    Scibelli, Filomena
    Vinciarelli, Alessandro
    ADVANCES IN NEURAL NETWORKS: COMPUTATIONAL INTELLIGENCE FOR ICT, 2016, 54 : 189 - 200
  • [24] EFFICACY AND SAFETY OF AGOMELATINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER: A PILOT STUDY
    Nukala, Srikrishna
    Komaram, Ravi Babu
    Palla, Jayasree
    Murthy, K. S. N.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2016, 7 (08): : 3517 - 3521
  • [25] High PLC-C level in major depressive disorder and its relationship with disease severity: a different perspective on coagulation in major depressive disorder
    Yilmaz, Seda
    Oner, Pinar
    NEUROPSYCHIATRIA I NEUROPSYCHOLOGIA, 2022, 17 (3-4): : 145 - 151
  • [26] A 1-Year, Open-Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder
    Robinson, Donald S.
    Kajdasz, Daniel K.
    Gallipoli, Susan
    Whalen, Heidi
    Wamil, Art
    Reed, Carol R.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 31 (05) : 643 - 646
  • [27] Depression and Major Depressive Disorder in Patients with Parkinson's Disease
    Inoue, Takeshi
    Kitagawa, Mayumi
    Tanaka, Teruaki
    Nakagawa, Shin
    Koyama, Tsukasa
    MOVEMENT DISORDERS, 2010, 25 (01) : 44 - 49
  • [28] PLASMA GALANIN IS A BIOMARICER FOR SEVERITY OF MAJOR DEPRESSIVE DISORDER
    Wang, Yong-Jun
    Yang, Yu-Tao
    Li, Hui
    Liu, Po-Zi
    Wang, Chuan-Yue
    Xu, Zhi-Qing David
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE, 2014, 48 (02) : 109 - 119
  • [29] Discovery and validation of a protein biomarker for the diagnosis and classification of disease severity of major depressive disorder
    Lee, You-Rim
    Lee, Jiyeong
    Kang, Hee-Gyoo
    CLINICA CHIMICA ACTA, 2023, 549
  • [30] Sexual Functioning in Patients With Recurrent Major Depressive Disorder Enrolled in the PREVENT Study
    Gelenberg, Alan J.
    Dunner, David L.
    Rothschild, Anthony J.
    Pedersen, Ron
    Dorries, Kathleen M.
    Ninan, Philip T.
    JOURNAL OF NERVOUS AND MENTAL DISEASE, 2013, 201 (04) : 266 - 273